- Home
- RNXT vs GDTC Comparison
RNXT vs GDTC Comparison
Compare RNXT & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- GDTC
- Stock Information
- Founded
- RNXT 2012
- GDTC 2018
- Country
- RNXT United States
- GDTC Singapore
- Employees
- RNXT N/A
- GDTC N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- RNXT Health Care
- GDTC Health Care
- Exchange
- RNXT Nasdaq
- GDTC Nasdaq
- Market Cap
- RNXT 40.7M
- GDTC 24.2M
- IPO Year
- RNXT 2021
- GDTC 2023
- Fundamental
- Price
- RNXT $1.12
- GDTC $2.28
- Analyst Decision
- RNXT Strong Buy
- GDTC Buy
- Analyst Count
- RNXT 2
- GDTC 1
- Target Price
- RNXT $7.50
- GDTC $5.00
- AVG Volume (30 Days)
- RNXT 666.9K
- GDTC 103.7K
- Earning Date
- RNXT 11-12-2025
- GDTC 01-01-0001
- Dividend Yield
- RNXT N/A
- GDTC N/A
- EPS Growth
- RNXT N/A
- GDTC N/A
- EPS
- RNXT N/A
- GDTC N/A
- Revenue
- RNXT $662,000.00
- GDTC $573,193.00
- Revenue This Year
- RNXT $2,895.35
- GDTC $5.37
- Revenue Next Year
- RNXT $313.04
- GDTC N/A
- P/E Ratio
- RNXT N/A
- GDTC N/A
- Revenue Growth
- RNXT N/A
- GDTC 63.03
- 52 Week Low
- RNXT $0.75
- GDTC $1.65
- 52 Week High
- RNXT $1.69
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- RNXT 45.47
- GDTC 61.26
- Support Level
- RNXT $1.06
- GDTC $1.95
- Resistance Level
- RNXT $1.15
- GDTC $2.43
- Average True Range (ATR)
- RNXT 0.11
- GDTC 0.18
- MACD
- RNXT -0.01
- GDTC 0.02
- Stochastic Oscillator
- RNXT 20.55
- GDTC 71.00
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.